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Abstract
Host cyclophilin (cyp) inhibitors, such as NIM811, efficiently inhibit replication of hepatitis C virus (HCV) and have
shown significant promise in recent clinical trials for the treatment of chronic HCV. It is therefore important to fully
understand the mechanism of action of these therapeutic agents. Data obtained from comprehensive systems
biology approaches have led to the hypothesis that the antiviral activity of cyclophilin inhibitors is mediated
through impairing the cellular machinery on which HCV relies to traffic cofactors necessary for formation of the
replication complex. Indeed, our results demonstrate when cyclophilins are inhibited by NIM811, lipid and protein
trafficking within the VLDL pathway is impaired. Following treatment of replicon or HCV infected cells with NIM811,
intracellular lipid droplets (LD) more than double in size and decrease in number. Changes in the LDs in response
to cyclophilin inhibition are dependent upon expression of viral proteins. Additionally, in cells treated with NIM811,
apoB accumulates in a crescent or ring shaped structure surrounding the enlarged LDs and is no longer secreted.
Silencing of cypA or cyp40 using siRNA had a similar effect on LD size and apoB localization as compound
treatment, suggesting these cyclophilins may play an important role in lipid and apoB trafficking. Interestingly, the
decrease in apoB secretion correlates with a decrease in release of viral particles in HCV infected cells. Altogether,
these results add a new level of complexity to the mechanism of action of cyclophilin inhibition, and suggest the
role for cyclophilins in the virus life cycle extends beyond replication to virus release.
Introduction
Chronic Hepatitis C virus (HCV) infection, a major
cause of chronic hepatitis, cirrhosis and hepatocellular
carcinoma, afflicts approximately 3% of the world’s
population [1]. The current standard of care is pegylated
interferon and ribavirin, which shows poor tolerability
and is only capable of achieving a sustained viral
response in half of genotype 1 infected patients [2].
Although new direct acting anti-virals (DAA) are on the
immediate horizon for treatment of HCV patients in the
clinic, the risk for resistance mutations arising in
response to these drugs necessitates continued develop-
ment of new therapeutic agents [3]. Cyclophilin inhibi-
tors, such as NIM811 and alisporivir, target host cell
proteins and have the capacity to increase the barrier to
resistance when used in combination with DAAs in
vitro [4-6]. As this class of compounds continues to be
investigated in the clinic with much success, it is
important to have a more thorough understanding of
their mechanism of action [7].
HCV is a small enveloped virus with a positive, single
strand RNA genome of ~9.6 kb that encodes a single
polyprotein. The polyprotein undergoes co- and post-
translational processing into 10 viral proteins, which
form the replication complex in association with the
membranous web. The membranous web consists of
viral proteins, replicating viral RNA and altered cellular
membranes from the endoplasmic reticulum (ER).
Formation of the membranous web is thought to protect
the replication complex from host innate defense
proteins so replication can proceed [8]. HCV replication
is tightly linked to lipid biology, and the necessity of
fatty acids and cholesterol for construction and mainte-
nance of a membranous web has been demonstrated
[9-12]. In the cell, the main source of neutral lipids is
the lipid droplet (LD), where they are stored in the form
of triacylglycerols (TAG) and cholesterol esters. When
needed, these neutral lipids are mobilized from the LD
to the ER and serve as substrates for lipid metabolism,
membrane synthesis and steroid synthesis [13].
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role in the life cycle for HCV, but perhaps the most
recognized of these are the cyclophilins (cyp). Cyclophi-
lins are peptidyl-prolyl isomerases that assist in protein
folding by catalyzing the cis/trans isomerization of the
peptidyl-prolyl bond [14]. In addition to their enzymatic
activity, other functions attributed to the cyclophilins
include mediating cholesterol transport, acting as pro-
tein chaperones, and RNA splicing [15]. In the case of
HCV, many cyps have been deemed important for viral
replication and possibly virus assembly [16-20]. CypA
emerges from these studies as the predominant cyclo-
philin, and is thought to not only assist in viral protein
folding, but also to enhance interactions between viral
proteins and RNA, polyprotein processing and replica-
tion complex formation [7]. In our hands, we find cypA,
cyp40 and cypH to be important for HCV replication
[17]. While the biological function of cyp40 is not com-
pletely characterized, this co-chaperone can be found in
complex with heat shock proteins (hsp90/hsp70) and
cholesterol [21].
Following the discovery that cyclosporin A (CsA) has
anti-viral activity when combined with interferon in
HCV patients, several non-immunosuppresive CsA
analogs, including NIM811 and alisporivir, have been
intensely investigated as a possible new therapy for
chronic HCV. NIM811 binds to cyclophilins with a
greater affinity than CsA, and this binding affinity corre-
lates with anti-viral activity in the HCV replicon assay
[4]. NIM811 is a powerful tool that allows the explora-
tion of the relationship between cyclophilin biology and
the virus life cycle. In pull down experiments using
immobilized compound, we found NIM811 binds to
proteins involved in intracellular trafficking [17]. Simi-
larly, an siRNA screen in HCV replicon cells identified
that proteins potentially involved in virus replication
were also involved in protein and lipid trafficking [17].
Taken together, these results have led to the hypothesis
that NIM811 may inhibit viral replication by impairing
the cellular machinery on which HCV relies upon to
traffic cofactors necessary for formation of an active
replication complex. Our results demonstrate that in
addition to altering lipid trafficking, as evidenced by an
accumulation of neutral lipids in LDs, cyp inhibition
also results in decreased apoB secretion through the
VLDL pathway. We find that cyclophilins are also
important for the secretion HCV, as HCV virion assem-
bly and release is highly dependent upon the VLDL
pathway and can be blocked by treatment with NIM811
[22]. Correspondingly, siRNAs specific to cypA or cyp40
in replicon cells have the same effect as NIM811 on the
LD size and apoB transport. These results suggest that
NIM811 mediated inhibition of cypA and cyp40 are
responsible for the changes in protein and lipid traffick-
ing and likely play a role in secretion of HCV.
Results
In light of our previous findings, we became interested
in understanding the interplay between cyclophilins,
HCV and lipid metabolism. The morphology of lipid
droplets is often indicative of the metabolic state of a
cell [23,24], so we began by investigating whether cyclo-
philin inhibition has any affect on lipid droplet mor-
phology. Following 24h treatment with 2μMN I M 8 1 1
(10X EC50), the lipid droplets were stained by BODIPY
494/503 in sg-1b replicon cells as well as JFH1 HCVcc
infected cells. We observed that the LDs were signifi-
cantly larger and decreased in number (top and bottom
panels, Figure 1A) following treatment with compound.
In contrast, the lipid droplets in a sg-1b NIM811 resis-
tant (NIMr) replicon cell line and in Huh7 naïve cells
remained as small punctate dots in the cytoplasm (sec-
ond and fourth panels, Figure 1A) [5]. We confirmed
that BODIPY 493/503 was staining LDs by using an
antibody specific for ADRP (adipocyte differentiation
related protein), a lipid droplet resident protein [13]
(data not shown). Quantification of lipid droplet size
over a range of NIM811 concentrations showed that
while the lipid droplets in sg-1b replicon cells double in
size in the presence of NIM811, the size of lipid droplets
remained constant in both sg-1b NIMr replicon cells as
well as naïve Huh7 cells (Figure 1B). These results indi-
cate the expression of wild type non-structural viral pro-
teins is necessary to observe changes in LD morphology.
A time course analysis of lipid droplets in the presence
of NIM811 demonstrated that lipid droplets begin to
increase in size within the first 8 hours of compound
treatment and become twice as large between 24h and
48h, whereas the NS3 protease inhibitor BILN2061 did
not alter the size of lipid droplets (Figure 1C). Similarly,
other cyclophilin inhibitors tested, CsA and sanglifehrin
A (SfA), resulted in significantly larger lipid droplets in
sg-1b replicon cells but not naïve Huh7 cells, confirming
this phenotype is specific to cyclophilin inhibition in the
presence of HCV proteins (Figure 1D).
Lipid droplets are the primary source of TAGs for
VLDL synthesis in hepatocytes [25]. VLDL particles are
formed in the liver through the interaction of apoB with
lipids including cholesterol, phospholipids and TAGs
[26]. To determine whether the alterations in lipid dro-
plets resulting from cyclophilin inhibition affected the
VLDL pathway, sg-1b replicon cells were treated with
NIM811 or DMSO vehicle control for 24h and stained
for apoB, the major protein component of VLDL [27].
Figure 2A and 2B show that in DMSO treated cells,
apoB is distributed throughout the cell and in the ER, as
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Figure 1 HCV replicon cells treated with NIM811 have enlarged lipid droplets. Wild type sub-genomic 1b (sg-1b) replicon, a sg-1b NIMr
replicon, Huh7.5 cells infected with JFH1 HCVcc or Huh7 naïve cells were grown in the presence of NIM811 or DMSO vehicle control. Following
compound treatment, cells were fixed, permeabilized and stained for lipid droplets using BODIPY 493/503. A representative image of the lipid
droplets in cells treated with 2μM NIM811 (10X EC50) for 24h is shown (A). B) sg-1b, sg-1b NIMr and naïve Huh7 cells were treated with
increasing concentrations of NIM811 for 48h. Images of lipid droplets were acquired and quantified by the Cellomics ArrayScan VTI HCS reader.
The object area of lipid droplets in each cell type averaged from three experiments is graphed ± standard deviation. C) sg-1b replicon cells were
treated with indicated compounds for 48h and the size of the lipid droplets quantified as in B. The object area of the lipid droplets are graphed
± standard deviation. BILN2061 is an NS3 protease inhibitor with a replicon EC50 of 2nM. D) sg-1b replicon cells were grown in the presence of
cyclosporin A (CsA, 8μM) or sanglifehrin A (SfA, 10μM) for 24hr. Lipid droplets were fixed and stained as in (A). A representative image is shown,
where green represents lipid droplets and blue represents the nuclei (DAPI).
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Figure 2 ApoB accumulates as crescents in the ER surrounding the lipid droplets of sg-1b replicon cells treated with NIM811.
Sg-1b replicon cells were grown in the presence of compound for 24h, after which they were fixed, permeabilized and stained using antibodies
specific for apoB, NS5A and PDI. BODIPY 493/503 was used to visualize lipid droplets, and DAPI for nuclei. A) ApoB (red) is dispersed throughout
the secretory pathway in sg-1b cells grown in the presence of DMSO. Following growth in NIM811, apoB forms ring-like and crescent shaped
structures surrounding the lipid droplets (green). B) In DMSO treated cells, some of the apoB protein in replicon cells is localized to the ER, as
shown by the overlapping staining pattern with the ER marker PDI. The ring-like and crescent shaped structures containing most of the
detectable apoB protein co-localize with PDI in the presence of NIM811.
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Figure 3 NS5A does not co-localize with apoB crescents in sg-1b replicon cells treated with NIM811. Sg-1b replicon cells were treated and
stained as in Figure 2. A) NS5A (red) localizes to regions that also contain apoB within replicon cells treated with DMSO, whereas NS5A and
apoB no longer co-localize in the presence of NIM811. B) NS5A and lipid droplets are in close apposition, but the two do not co-localize in
sg-1b replicon cells regardless of compound treatment.
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accumulates in ring-like structures around the enlarged
lipid droplets, similar to the apoB crescents described
previously [28]. The apoB crescents partially co-localize
with PDI, a protein that is retained in the ER by its
KDEL sequence [26], indicating that the enlarged lipid
droplets are either within the ER or in very close proxi-
mity with the ER membrane (Figure 2B). Although
NS5A was found to co-localize with some of the apoB
in DMSO treated replicon cells, as shown previously
[22], apoB in NIM811 treated cells no longer localizes
w i t hN S 5 A( F i g u r e3 A ) .W es e et h es a m es t a i n i n g
pattern when we use an antibody to NS3 (data not
shown). These results further support that trafficking of
apoB in replicon cells is interrupted when cyclophilins
are inhibited. Although NS5A can be found close to
lipid droplets, we are unable to detect any co-localiza-
tion of NS5A with the lipid droplet in the sub-genomic
replicon cell system (Figure 3B). The small accumula-
tions of NS5A found in NIM811 treated replicon cells
co-localize with calnexin (data not shown) and likely
reflect unfolded protein resulting from cyclophilin inhi-
bition [18]. Similar results to those shown in Figures 2
and 3 were obtained with JFH1 HCVcc infected cells
(data not shown).
To further understand the data suggesting viral pro-
tein expression is necessary for cyclophilin inhibition to
result in the enlarged lipid droplet phenotype and apoB
crescent formations, we next compared apoB expression
and secretion in sg-1b replicon cells and naïve Huh7
cells. Interestingly, there is a ~3-fold increase in apoB in
the supernatant from Huh7 cells containing viral
proteins (sg-1b) compared with naïve Huh7 cells
(Figure 4A). There is also a 3.1 fold increase in apoB in
whole cell lysates (representing intracellular apoB) from
sg-1b cells compared with Huh7 cells. To determine
whether the formation of apoB crescents in NIM811
treated cells affected apoB secretion, we measured the
amount of apoB in the supernatants of sg-1b replicon
cells and naïve Huh7 cells by ELISA. As shown in
Figure 4B, we observed a dose dependent decrease in
the amount of apoB in the supernatant following 48h
treatment with NIM811. The effect of cyclophilin inhibi-
tion on apoB secretion is more pronounced in sg-1b
cells expressing viral proteins compared with naïve
Huh7 cells, where we consistently observe an ~20%
difference at each concentration (p < 0.01 comparing
secretion from sg-1b and naïve Huh7 cells at each
concentration by paired students t-test). These results
confirm that secretion of apoB is impaired when cyclo-
philins are inhibited by NIM811.
The assembly and release of infectious HCV particles
is tightly associated with the VLDL secretory pathway
[22,29]. Given our results demonstrating that NIM811
inhibits the secretion of apoB from replicon and HCVcc
infected cells, we hypothesized that NIM811 could also
block the release of infectious particles. To test this
hypothesis, we examined viral RNA and infectious
particle release in the supernatant of infected cells 8h
post-compound treatment to minimize the effect of
compound on replication. It was shown previously that
8h is sufficient to detect a change in particle release
using GolgiPlug (brefeldin A) [29]. Huh7.5 cells were
infected with JFH1 HCVcc and incubated for three
days, which resulted in >80% HCV positive cells (data
not shown). We used GolgiPlug as a control, as this
compound inhibits intracellular transport and has been
previously demonstrated to inhibit HCV release from
infected cells without affecting virus replication [29]. As
expected, GolgiPlug resulted in an accumulation of
HCV RNA and infectious particles. The addition of
0.2μMN I M 8 1 1( ~ E C 50, data not shown) to infected
cells resulted in a 50% decrease in the release of both
HCV RNA and infectious particles into the supernatant
compared with DMSO control (Figure 5A and 5C). The
release is inhibited further by addition of 2μM NIM811,
which resulted in a 75% decrease. Analysis of the intra-
cellular content reveals that the amount of HCV RNA
and infectious particles in NIM811 treated samples is
equivalent to the DMSO control (Figure 5B and 5D). In
contrast to GolgiPlug treated cells, there is a lack of
accumulation of HCV RNA or infectious particles in
NIM811 treated cells, which can be explained by the
effect of NIM811 on replication. These results suggest
that cyclophilins are not only important for replication;
they also play a potential role in the assembly/egress
process for HCV.
A B
Figure 4 The effect of viral proteins and cyclophilin inhibition on
apoB secretion. A) Supernatants and whole cell lysates from equal
numbers of sg-1b replicon and naïve Huh7 cells were used to
quantify apoB protein by ELISA. The average apoB protein levels
from two experiments was normalized to naïve Huh7 cells and
graphed as fold change in apoB protein. B) Sg-1b replicon and
Huh7 naïve cells were treated with varying concentrations of
NIM811 for 48h. ApoB was measured in the supernatants by ELISA.
The amount of apoB protein was normalized to DMSO controls for
each cell type and plotted as relative secretion ± standard deviation
from three experiments.
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lins and lipid droplets, we used siRNA to knock down
cyclophilin protein expression in sg-1b replicon cells
and examined the lipid droplets. Western blot analysis
(Figure 6A) demonstrates that siRNAs targeting cypA,
cypB and cyp40 result in a significant reduction in pro-
tein expression. Although cypA is still abundant in the
cell following siRNA transfection, this level of protein
reduction was sufficient to reduce replication by 60% at
72h and 80% by 96h (Figure 6B). A modest, but statisti-
cally significant, decrease in replication is seen with
siRNA to cyp40. These results are similar to those pre-
viously published using a sg-1b replicon expressing luci-
ferase [17]. Interestingly, inhibition of replicon activity
by siRNA correlates with an increase in lipid droplet
size (Figure 6C). Compared with the RISC free siRNA
control, cypA and cyp40 siRNAs result in an approxi-
mately 3-fold increase in lipid droplet size in sg-1b
replicon cells, as quantified by high content imaging
(Figure 6D). In contrast, cypB siRNA does not affect the
size of lipid droplets. Interestingly, there is no difference
in the size of lipid droplets when naïve Huh7 cells are
transfected with cyclophilin siRNAs (Figure 6D), further
supporting the data from experiments using NIM811
treatment. As shown in Figure 7, apoB crescents accom-
pany the enlarged lipid droplets that form in sg-1b repli-
con cells transfected with siRNA to cypA or cyp40, but
not cypB. These data confirm that the increased lipid
droplet size and decreased apoB secretion upon
NIM811 treatment is mediated through inhibition of
cypA and cyp40.
Discussion
The current standard of care for chronically infected
HCV patients lacks efficacy and does not achieve a sus-
tained viral response in all patients, especially those
infected with genotypes 1 and 4 [2]. While promising,
the new DAAs coming into the clinic present the
AB
CD
Figure 5 NIM811 blocks the release of HCV RNA and infectious virions from infected cells. Huh7.5 cells were infected with JFH1 HCVcc for
three days. Following infection, cells were washed and treated with the indicated compounds for 8h. Intracellular and extracellular virus was
harvested as described in materials and methods, and assayed for viral RNA content by qRT-PCR (A and B) or infectivity (C and D). GolgiPlug
prevents secretion of infectious particles, resulting in an accumulation of intracellular viral RNA and infectious particles. There is a dose
dependent decrease in viral RNA and infectious particles in the media of infected cells treated with NIM811.
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Page 7 of 13additional challenge of resistance mutations arising, thus
necessitating additional approaches [3]. By targeting a
cellular factor, cyclophilin inhibitors have the potential
to increase the barrier of resistance as well as provide
broad genotype coverage [4,7]. Cyclophilins are best
known for their role as cellular chaperones in protein
folding and trafficking, and many of the HCV non-
structural proteins have been identified as substrates [7].
As cyclophilins appear to be important in the life cycle
of a number of viruses, including HIV, human papillo-
mavirus (HPV), cytomegalovirus (CMV), and vesicular
stomatitis virus (VSV), it is of utmost importance to
cypA
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Figure 6 Enlarged lipid droplets correlate with inhibition of HCV replication using siRNA knockdown. A) sg-1b replicon cells were transiently
transfected with siRNA to target cypA, cypB and cyp40. A RISC-free siRNA construct was used as a control. Whole cell lysates were analyzed for
target protein expression by Western blot at 72h and 96h post-transfection. B) Total RNA from siRNA transfected cells was extracted and used for
quantitative real-time RT-PCR to measure copies of HCV. Replication in RISC-free control cells was set to 100% for each time point. Results are the
average of 4 independent experiments, ± standard deviation. CypA and cyp40 siRNA result in a statistically significant decrease in replicon activity,
p < 0.01 for cypA and p < 0.05 for cyp40 compared to RISC-free siRNA by Students paired t-test. C) At 96h post-transfection, lipid droplets were
visualized as described. Representative images for each siRNA are shown. D) 20X images were acquired and quantified by the Cellomics ArrayScan
VTI HCS reader. The mean fluorescence intensities for BODIPY 493/503 were normalized to the RISC free siRNA control. Those siRNA constructs that
resulted in inhibition of HCV [17] also caused the lipid droplets to become enlarged, similar to what is seen with NIM811 treatment.
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tionship with viruses. Here, we use NIM811 as a tool
cyclophilin inhibitor and find that in addition to viral
replication, cypA and cyp40 are important for the
release of infectious HCV particles.
In Huh7 cells expressing viral proteins, either from the
replicon or JFH1 HCVcc, NIM811 treatment results in
enlarged lipid droplets and apoB crescent formation.
These changes correlate with what is seen in replicon
cells transfected with siRNA to cypA or cyp40, indicat-
ing that the effect seen with NIM811 is due to inhibi-
tion of cypA and/or cyp40. In contrast, we were unable
to detect any change in the lipid droplets or apoB traf-
ficking in Huh7 cells. Altogether, these results lead to
the question: why does NIM811 induce such dramatic
changes only in the presence of viral proteins?
Hepatocytes are responsible for a large proportion of
cholesterol and lipid synthesis, which is assembled into
VLDL particles along with apoB, allowing the lipids to
be transported in the bloodstream and used as an
energy source. The life cycle of HCV is tightly asso-
ciated with lipid metabolism, including the secretory
pathway for VLDL, and the availability of lipids (fatty
acids, cholesterol and sphingolipids) directly influences
the rate of HCV replication [9,17]. It is therefore not
surprising that replication of the virus is restricted to
this host cell type [9,11,12,30,31]. Core and NS5A are
thought to induce changes in the expression of genes
which are involved in lipid metabolism and cholesterol
regulation [10,31]. These changes create a lipid rich
environment which favorably supports the formation of
the membranous web as well as assembly, while inadver-
tently leading to steatosis [10,31,32]. Expression of NS4B
alone can induce formation of the membranous web
independent of any other viral genes, and it has recently
been demonstrated to stimulate signaling pathways that
result in accumulation of lipids [33,34]. Altogether,
these data indicate that in cells expressing viral proteins,
there is an overall up-regulation of lipid synthesis.
Taken with our observations that the effect of NIM811
is more pronounced in cells expressing viral proteins
than in naïve Huh7 cells, and apoB expression and
secretion is upregulated in sg-1b replicon cells, we
hypothesize that NIM811 is blocking pathways stimu-
lated by viral proteins, resulting in an accumulation of
excess lipids and apoB.
TAG stored in LDs is transferred to the ER lumen to
interact with apoB and form pre-VLDL particles [26].
Many chaperones are known to assist in this process,
including cyclophilin B [35]. By siRNA knockdown, we
demonstrate that cypB does not have a role in the
alterations in lipid droplets and apoB crescent forma-
tion, whereas cypA and cyp40 do. One explanation may
be that cypB protein is incompletely eliminated by
siRNA transfection, and the small amount of remaining
protein is sufficient to accomplish this function. A more
intriguing explanation is independent of cypB, and
involves a role for cypA and cyp40 in delivering choles-
terol and TAG from the lipid droplet to the ER to form
pre-VLDL particles with apoB. A complex of cypA,
cyp40, caveolin and Hsp56 form a chaperone complex
which transports cholesterol within the cytoplasm. In
the presence of CsA, this interaction is disrupted and
transport of cholesterol is interrupted [36]. Caveolin has
b e e ns h o w nt ob et a r g e t e dt ot h ec o r eo fL D si n
addition to other membranes within the cell, making it
likely that the caveolin/cypA/cyp40 complex can shuttle
cholesterol between the LD and ER [37]. ApoB crescent
formation increases when cells are treated with inhibi-
tors of cholesterol synthesis, and if cholesterol is not
available for VLDL synthesis, the secretion of apoB is
impaired [26]. Thus, the possibility exists that NIM811,
like CsA, disrupts the interaction of cholesterol with
cypA and cyp40, thereby preventing cholesterol from
leaving the LD and trafficking to the ER, where it would
interact with apoB to form pre-VLDL. Binding of
NIM811 to cypA and cyp40 and the subsequent block
in caveolin/chaperone/cholesterol complex formation at
the LD would therefore result in a lack of cholesterol
trafficking into the ER for VLDL synthesis and subse-
quent apoB crescent formation. This explanation pro-
vides for the enlarged lipid droplets that are seen upon
treatment with NIM811 as well as the accumulation of
apoB that is seemingly stuck in the ER.
Perhaps the most interesting finding presented here is
NIM811 inhibits the egress of virus particles from JFH1
HCVcc infected cells. The mechanism whereby cyclo-
philin inhibition may target this process is at least two
tiered. There is mounting evidence that NS2 plays a
RISCfree
cypB
cypA
cyp40
cypA
cyp40
Figure 7 ApoB crescents form in replicon cells transfected with
siRNA to cypA and cyp40, but not cypB. Sg-1b cells were
transfected with siRNA as in Figure 6. At 96h post-transfection, cells
were fixed, permeabilized and stained for lipid droplets (green) and
apoB (red) as described. Representative images are shown.
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particles, through interactions with various viral proteins
including the envelope proteins, p7, NS3 and NS5A
[38-43]. In a recent report, NS2 has also been added to
the list of viral proteins that may require cypA for
proper folding [44]. In support of this notion, it was
found that full length genomes are more sensitive to
inhibition by cyclophilin inhibitors, and this increased
sensitivity is dependent upon the presence of NS2 [44].
If NS2 is indeed crucial for the production of virus, and
cypA is important for NS2 function, NIM811 inhibition
of virus secretion may be at the level of NS2 protein
folding mediated by cypA. While this explanation takes
into account the activity of NIM811 in HCVcc infected
cells, NIM811 affects apoB and the LDs in sub-genomic
replicon cells, suggesting that other viral proteins are
also involved in this process.
The second tier of NIM811 mediated inhibition of
secretion is by disrupting the intricate relationship
between VLDL assembly and HCV particle assembly
[29,45-47]. VLDL assembly can be delineated into two
steps, which are separated by the cellular compartment
in which they occur. In the first step, microsomal trigly-
ceride transfer protein (MTP) transfers triglycerides
from the LD or the ER to apoB in the lumen of the ER.
The second stage of assembly is thought to occur in the
ER/golgi luminal compartment, where additional trigly-
cerides are added to the complex, thereby decreasing its
density. Both apoB and apoE are important structural
components of VLDL [48]. HCV circulates in the
plasma of infected patients in a complex with VLDL,
and agents that inhibit the assembly of VLDL block the
secretion of HCV [22]. In addition, both apoB and apoE
have been shown to be important host factors in the
assembly and/or egress stage of the HCV life cycle, alto-
gether indicating that HCV hijacks the VLDL assembly
pathway for assembly and egress of viral particles. While
it is increasingly clear that HCV assembly and release is
dependent upon the VLDL machinery, the exact details
of where the virus enters the pathway have not been
elucidated [29,45-47]. NIM811 appears to block VLDL
assembly at the stage where lipids would be transferred
from the LD, which is closely associated with the ER, to
apoB in the ER membrane, preventing apoB from enga-
ging the secretory pathway. It is tempting to speculate
that this is also where assembled viral particles may
become trapped inside of the cell in the presence of
NIM811, giving the decrease inv i r u ss e c r e t i o ns e e ni n
the JFH1 HCVcc infected cells.
In summary, we have found that the lipid trafficking
function previously demonstrated for cypA and cyp40
plays an important role in the HCV life cycle [36]. It
is likely that lipid trafficking is critical at multiple stages
in the virus life cycle, including formation and
maintenance of a replication competent membranous
web and secretion of the virus. We now show that in
addition to inhibition of HCV replication, NIM811 also
causes a block in the VLDL pathway resulting in
decreased virus release. That cyclophilin inhibitors are
now attributed to blocking more than one stage in the
virus life cycle lends substantial support for their use in
combination with DAAs in the clinic. By targeting
multiple stages, these mechanisms may contribute to an
enhanced potency of cyclophilin inhibitors, including
NIM811 and alisporivir, and by extension increase the
barrier to resistance giving infected patients a more
favorable outcome [44].
Materials and methods
Compounds
NIM811 is a cyclophilin inhibitor with an EC50 of
200nM [5]. BILN2061 is an NS3 protease inhibitor with
a replicon EC50 of 2nM. All compounds were isolated
or synthesized at Novartis (Basel, Switzerland).
Cells
The subgenomic genotype 1b (Con1) HCV replicon cell
line, Clone A (designated as sg-1b WT) was obtained
from Charles Rice and Apath LLC (St. Louis, Missouri)
[49]. NIM811 resistant (NIMr) cells were generated by
culturing sg-1b replicon cells in media with increasing
concentrations of NIM811, as described previously [5].
Cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 2 mM L-glutamine, 0.1
mM nonessential amino acids, and 10% fetal bovine
serum (FBS). Replicon cells were maintained in media
containing 1 mg/mL geneticin. Huh7.5 cells were used
to generate JFH1 infectious virus as described [50].
Antibodies and Reagents
BODIPY 493/503, DAPI and Alexa Fluor conjugated
secondary antibodies for microscopy experiments were
purchased from Molecular Probes (Invitrogen). BODIPY
493/503 was dissolved in DMSO at 1 mg/mL and used at
1μg/mL. Rabbit polyclonal antibodies to apoB (ab20737),
cyclophilin A (ab41684) and cyclophilin B (ab16045) as
well as GAPDH-HRP were obtained from Abcam. Rabbit
polyclonal antibody to cyclophilin 40 was from Affinity
Bioreagents (PA3-022). Mouse anti-PDI antibody was
purchased from Assay Designs (SPA-890). Mouse
monoclonal antibody to HCV NS5A was from Meridian
Life Sciences (C65388M). ECL anti-rabbit IgG-HRP
secondary antibody was from GE Healthcare.
Indirect Immunofluorescence Microscopy
For confocal microscopy experiments, cells grown in
poly-L-lysine coated glass bottom dishes (MatTek
Corp.) were fixed with 4% paraformaldehyde for 10 min.
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dissolved in PBS containing 0.2% gelatin (PBS-G) for
30 minutes. Primary and secondary antibodies were
diluted in PBS-G and incubated with the cells for 2 h or
45 min. at room temperature, respectively. After
antibody staining, cells were washed with PBS-G and
incubated with DAPI and BODIPY 493/503 for 30 min-
utes. Images were obtained using an Axiovert LSM 510
META laser scanning confocal microscope using a 63X
oil immersion objective (Zeiss). Data were processed
using LSM 510 Meta software (Zeiss) and images were
converted to TIFFs and assembled using ImageJ soft-
ware (National Institutes of Health, Bethesda, MD).
For quantification of immunofluorescence, cells were
grown in 96 well black plates with clear bottoms
(Costar). After fixing, permeabilizing and staining (as
above), 20X images were acquired and analyzed using a
Cellomics ArrayScan VTI High Content Imager and
Cellomics ArrayScan software (Thermo Fisher
Scientific).
ApoB ELISA
Sg-1b replicon cells were plated at 1 × 10
4 cells/well in
a 96 well dish. The next day, media was removed and
replaced with complete DMEM containing compound
diluted in DMSO (0.5% final concentration of DMSO).
After 48h of compound treatment, the supernatants
were collected and cleared by centrifugation. ApoB
release into the supernatants was quantified using the
Human ApoB ELISA kit from AlerCHEK (Portland,
ME), Inc according to manufacturer’s instructions, with
one exception. Supernatants were diluted directly 1:1
with the Apo B specimen diluent provided, with no
initial PBS dilution.
siRNA Transfection
Sg-1b replicon cells were reverse transfected with
siGENOME smartpool siRNAs from Dharmacon as
described [17]. For confocal microscopy experiments,
the transfection mixture and cells were plated in poly-
L-lysine coated glass bottom 96 well dishes. Cells were
fixed and stained at 96h post-transfection. For quantifi-
cation, the transfection mixture and cells were plated in
black with clear bottom 96 well plates and mean fluor-
escence intensity (MFI) as well as mean area of lipid
droplets was quantified by high content imaging (as
above). MFI values are normalized to a RISC-free siRNA
control.
Western Blots
At 72h and 96h post-transfection, sg-1b replicon cells
were lysed with RIPA buffer (Sigma Aldrich) containing
protease cocktail (Thermo Fisher Scientific). Protein
concentrations were determined by BCA Protein Assay
(Pierce). Equal amounts of protein mixed with
4X NuPAGE LDS Sample buffer were boiled at 70°C for
10 min., separated by SDS-PAGE, transferred to nitro-
cellulose by iBlot (Invitrogen) and blocked with 3%
bovine serum albumin (BSA) diluted in PBS plus 0.05%
Tween-20 (PBST). Primary antibodies were diluted in
PBST and incubated with blots overnight at 4°C
followed by a 1h incubation with HRP-conjugated sec-
ondary antibody. Blots were visualized using ECL
(Thermo Fisher Scientific).
Virus Release Assay
Huh7.5 cells were infected with JFH1 HCVcc for three
days to allow the virus to spread throughout the mono-
layer. Three days post infection, cells were washed 5X
with complete DMEM, media was replaced with com-
plete DMEM containing compound in duplicate and
incubated at 37°C for 8h. For extracellular virus, one set
of supernants was collected and the viral RNA
extracted using the QIAamp viral RNA mini kit
(Qiagen) according to the manufacturer’s instructions,
and used to quantify the amount of extracellular viral
RNA released. The second set of supernatants was
purified using HCV Pure HCV Purification Mini col-
umns (BioVintage) to eliminate any compound from
the supernatants. Purified virions were used to deter-
mine extracellular infectivity. For intracellular virus,
one set of cells was washed with PBS and total RNA
extracted using RNeasy RNA Mini kit (Qiagen) accord-
ing to the manufacturer’s instructions. For intracellular
infectivity, the second set of cells was trypsinized,
pelleted, resuspended in complete DMEM and lysed by
four cycles of freeze-thaw (alternating between a
dry-ice/ethanol bath and 37°C water bath).
Infectivity
To measure infectivity of the extracellular and intracel-
lular virus, purified supernatant or lysate was used to
infect naïve Huh7.5 cells. At 72hpi, the infectivity read
out was measured as renilla luciferase (Promega). Infec-
tivity was normalized to the DMSO control, set to 100%.
Quantitative Real Time RT-PCR
Copies of HCV RNA in the extracellular supernatant and
intracellular lysate were quantified using the Superscript
III Platinum One-step Quantitative RT-PCR System (Invi-
trogen) with the Applied Biosystems 7900HT Real Time
PCR System and HCV specific primers and probes. HCV
primer sequences: (sense) 5’-CGGGAGAGCCATA
GTGG-3’ (anti-sense) 5’- AGTACCACAAGGCC TT
TCG-3’. Probe: 5’-6FAM-CTGCGGAACCGGTGAGTA-
CAC-TAMRA-3’. Intracellular HCV RNA values were
normalized to a GAPDH internal control (TaqMan Assay,
Applied Biosystems). Results from four independent
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were averaged and normalized to the DMSO control.
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